Why do phase III trials of promising heart failure drugs often fail? the contribution of “regression to the truth”

This publication has 17 references indexed in Scilit:

• Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
  International Journal of Cardiology, 2002
• Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure
  Circulation, 2002
• Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH
  European Journal of Heart Failure, 2002
• Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure
  Circulation, 2001
• Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
  The Lancet, 2000
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
  The Lancet, 2000
• A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure
  New England Journal of Medicine, 1998
• Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
  Published by Elsevier ,1997
• Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
  New England Journal of Medicine, 1996
• Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure
  New England Journal of Medicine, 1993